Adherium (ASX:ADR), a digital health company focussed on improving medication adherence and patient outcomes, has confirmed US FDA clearance for its SmartTouch monitoring device for AstraZeneca’s Symbicort aerosol inhaler.
The 'SmartTouch for Symbicort' is a device installed onto a patient’s inhaler to monitor and encourage medication adherence as part of a self-management plan for respiratory conditions such as asthma and COPD.
“The SmartTouch for Symbicort is the most advanced Smartinhaler product to date for Adherium and a key product in our strategic collaboration with AstraZeneca by bringing the benefits of digital monitoring to patients and their physicians," said Arik Anderson, CEO of Adherium.
"With each new generation, our Smartinhalers get smaller, easier to use, and incorporate more sensors that generate higher quality data, and higher levels of medication adherence. This is Adherium’s third U.S. 510(k) clearance to market. In addition, the company has secured clearances in Europe, Canada, Australia, China, Singapore and New Zealand.”
The device records the date and time the inhaler is used and automatically transmits this information to an app on the patient’s phone or tablet. The SmartTouch stores the history of patient medication usage patterns.
The SmartTouch can be used in home monitoring programs, such as hospital re-admission prevention programs, where maintaining medication adherence after hospital discharge is a key objective. Its design includes three buttons that help patients easily access the audio visual-reminders, battery monitoring, and Bluetooth low-energy pairing features.